Stereotaxis Inc (STXS) - חוב להון עצמי

The market price confirmed by the chart demonstrates the resilience of Stereotaxis, Inc. (STXS), which is protected by unique patents and the complexity of equipment replacement. Stereotaxis, Inc. (STXS) develops robots for catheter ablation, providing physicians with safe remote navigation in the arrhythmia treatment segment. Revenues are based on the sale of systems to cardiac centers and the regular sale of disposable sensors, while the separate_debt_total_eq metric stands at 0.32.

This ratio determines the degree of financial leverage by comparing total liabilities to the business's own equity. The trend of the total debt-to-equity ratio reflects the balance between debt financing and shareholder value. The calculation is based on 10-Q and 10-K reporting data with daily adjustments for market capitalization. A low debt load minimizes default risks. For Stereotaxis, Inc. (STXS), such stability underscores its status as a defensive asset within the independent cycle of medical innovation.